Tags : Lexicon

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More

Sanofi Terminates its Four Years Alliance with Lexicon for Zynquista

Shots: Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista for T1D & T2D and coordinate with Sanofi in the transition of ongoing clinical studies and other activities In Jul’2019, Sanofi has terminated its 4yrs. […]Read More

Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program

Shots: The three P-III studies (SOTA-MET, SOTA-CKD3, SOTA-CKD4) involves assessing of Zynquista vs PBO in patients with T2D. The first two studies resulted in meeting its 1EPs i.e, @26wks. reduction in HbA1c while SOTA-CKD4 did not demonstrate a reduction in HbA1c Additionally, Sanofi to terminates its development and commercialization agreement with Lexicon for Zynquista in […]Read More

Sanofi and Lexicon’s Zynquista (sotagliflozin) Receive EU’s MAA to Treat

Shots: The authorization is based on inTandem study consisting of three P-III trials assessing sotagliflozin (200/400 mg) vs insulin as monothx in 3000 adults with inadequately controlled T1D The study resulted reduction in average blood sugar (HbA1c), body weight, systolic blood pressure, improvement of time in target blood sugar range, patient-reported outcomes within 24 weeks […]Read More